Genovis is launching FabULOUS this October. The product, which complements FabRICATOR, has already been tested by key customers in Europe and the US with positive results and is now being launched in a first phase through in-house sales and later through the company’s global distributor network. "This new product is a completely new enzyme that offers our customers several alternative strategies for characterization of antibody molecules. Fabulous is a great addition to FabRICATOR and by using the two products together, the customer gets a fast method to characterize the hinge region of an antibody in detail, which is important in many antibody drug conjugate (ADC) drug candidates. Our R & D activities focus on products that can save time, simplify work and improve the quality of analyses for our customers and FabULOUS is a great example of it," says Sarah Fredriksson, CEO of Genovis. Genovis has developed the product FabULOUS, which can quickly generate fragments from IgG molecules. FabULOUS is a recombinant enzyme that cleaves IgG specifically, thereby generating three intact fragments of an antibody. The yield is high, the reaction rate is fast and the enzyme does not generate any further fragmentation. Customers will primarily use the product for screening of new drug substances and quality control of new antibody-based drugs.
GenovisÊ¼ business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes (protein engineering portfolio) in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging. Genovis shares are listed on NASDAQ OMX First North, and Thenberg Fondkommission is Certified Adviser for the Company, t: +46 (0)31-745 50 00.
Sarah Fredriksson, CEO Genovis AB is attending and speaking at the European Antibody Congress 2013, and both Sarah and Genovis will be available to discuss this further at their exhibition stand. Take a look at the event website now and book your place too!